# Milestone Pharmaceuticals Milestone Pharmaceuticals is an Asset Manager based in Montreal, Canada. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Montreal, Canada - **Region:** North America - **Address:** Montreal, Quebec, Canada - **Founded:** 2005 - **Assets under management:** Undisclosed - **Website:** milestonepharma.com ## Regulatory record - **Reports private funds:** No ## About Milestone Pharmaceuticals was founded in 2005 and trades on Nasdaq under the ticker MIST. Joseph Oliveto took over as CEO in 2021, inheriting a company built around one molecule: etripamil, a fast-acting calcium channel blocker delivered as a nasal spray. The firm's intellectual property originates from academic work on as-needed cardiac rhythm management, a departure from daily maintenance drugs. The company allocates nearly all its resources to the clinical development of etripamil. Its lead indication, paroxysmal supraventricular tachycardia, affects roughly 2 million Americans, and Milestone's Phase 3 RAPID trial met its primary endpoint in 2023. A second trial for atrial fibrillation with rapid ventricular rate is ongoing. Manufacturing is outsourced, and the firm has no revenue-generating products. It funds operations through periodic equity offerings convertible debt arrangements with institutional biotech investors. Post-trial data readout in 2023, Milestone cut its workforce by roughly 80% to preserve cash and filed a New Drug Application with the FDA in October 2024, with a PDUFA target action date set for May 2025. The company maintains a small footprint in Montreal, Quebec, with a US corporate presence in Charlotte, North Carolina. As of early 2025, the firm had approximately $70 million in cash and equivalents, though it disclosed going concern language in its filings, making the FDA decision an existential event. Milestone's structural differentiator is its binary event-driven risk profile. It is a single-asset public company with no diversification, no platform technology, and no partner revenue streams. Succession planning is effectively contingent on regulatory approval and potential commercialization or acquisition, making this a pure play on whether a single nasal spray can recast the standard of care for episodic cardiac rhythm disorders. ## Sectors - Healthcare Services ## Offices - Charlotte, NC, United States ## People - Joseph Oliveto — Chief Executive Officer - David Bharucha — Chief Medical Officer - Amit Hasija — Chief Financial Officer ## Questions ### How does Milestone Pharmaceuticals fund its operations without product revenue? Milestone is a pre-revenue stage biotech that funds clinical development and operations through periodic public equity offerings and convertible note arrangements with institutional healthcare investors. The firm reported approximately $70 million in cash and equivalents as of early 2025, but its filings include a going concern warning, meaning its ability to continue as an operating entity depends heavily on the FDA outcome or raising additional capital. ### What makes etripamil different from existing cardiac arrhythmia treatments? Etripamil is formulated as a patient-administered nasal spray designed to rapidly terminate episodes of supraventricular tachycardia within minutes, without requiring an intravenous line or a hospital visit. Current standard of care often involves patients going to an emergency department to receive intravenous adenosine or verapamil. Etripamil aims to shift that treatment to an at-home, on-demand model. ### What led to the significant staff reduction at Milestone in 2023? Following the Phase 3 RAPID trial data readout in 2023, Milestone reduced its workforce by roughly 80% to conserve cash ahead of its FDA submission. The decision reflected the company's transition from a clinical trial execution phase to a regulatory filing and potential pre-commercialization phase, requiring fewer internal resources until the drug's regulatory path is resolved. ### Does Milestone have any pipeline candidates beyond etripamil? No. Milestone is a single-asset company. Nearly all corporate resources are allocated to the etripamil program for paroxysmal supraventricular tachycardia and a Phase 2-stage indication for atrial fibrillation with rapid ventricular rate. The firm has no platform technology and does not invest in early-stage discovery, making its public market value a binary outcome wager on etripamil's approval and commercialization. ## Related profiles - [Belpointe PREP](https://altss.com/profile/belpointe-prep-llc) - [Finwise Bancorp](https://altss.com/profile/finwise-bancorp) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/milestone-pharmaceuticals-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology